Opin vísindi

Fletta eftir höfundi "Backer, Vibeke"

Fletta eftir höfundi "Backer, Vibeke"

Röðun: Raða: Niðurstöður:

  • Icon
    International severe asthma registry (ISAR): protocol for a global registry 
    FitzGerald, J. Mark; Tran, Trung N.; Alacqua, Marianna; Altraja, Alan; Backer, Vibeke; Bjermer, Leif; Björnsdóttir, Unnur; Bourdin, Arnaud; Brusselle, Guy; Bulathsinhala, Lakmini; Busby, John; Canonica, Giorgio W.; Carter, Victoria; Chaudhry, Isha; Cho, You Sook; Christoff, George; Cosio, Borja G.; Costello, Richard W.; Eleangovan, Neva; Gibson, Peter G.; Heaney, Liam G.; Heffler, Enrico; Hew, Mark; Hosseini, Naeimeh; Iwanaga, Takashi; Jackson, David J.; Jones, Rupert; Koh, Mariko S.; Le, Thao; Lehtimäki, Lauri; Lúðvíksdóttir, Dóra; Maitland-van der Zee, Anke H.; Menzies-Gow, Andrew; Murray, Ruth B.; Papadopoulos, Nikolaos G.; Perez-de-Llano, Luis; Peters, Matthew; Pfeffer, Paul E.; Popov, Todor A.; Porsbjerg, Celeste M.; Price, Chris A.; Rhee, Chin K.; Sadatsafavi, Mohsen; Tohda, Yuji; Wang, Eileen; Wechsler, Michael E.; Zangrilli, James; Price, David B. (Springer Science and Business Media LLC, 2020-08-14)
    Background: Severe asthma exerts a disproportionately heavy burden on patients and health care. Due to the heterogeneity of the severe asthma population, many patients need to be evaluated to understand the clinical features and outcomes of severe ...
  • Icon
    Nordic consensus statement on the systematic assessment and management of possible severe asthma in adults 
    Porsbjerg, Celeste; Ulrik, Charlotte; Skjold, Tina; Backer, Vibeke; Laerum, Birger; Lehman, Sverre; Janson, Crister; Sandstrøm, Thomas; Bjermer, Leif; Dahlen, Barbro; Lundbäck, Bo; Ludviksdottir, Dora; Björnsdóttir, Unnur; Altraja, Alan; Lehtimäki, Lauri; Kauppi, Paula; Karjalainen, Jussi; Kankaanranta, Hannu (Informa UK Limited, 2018-01)
    Although a minority of asthma patients suffer from severe asthma, they represent a major clinical challenge in terms of poor symptom control despite high-dose treatment, risk of exacerbations, and side effects. Novel biological treatments may benefit ...
  • Icon
    A rare IL33 loss-of-function mutation reduces blood eosinophil counts and protects from asthma 
    Smith, Dirk; Helgason, Hannes; sulem, patrick; Björnsdóttir, Unnur Steina; Lim, Ai Ching; Sveinbjornsson, Gardar; Hasegawa, Haruki; Brown, Michael; Ketchem, Randal R.; Gavala, Monica; Garrett, Logan; Jónasdóttir, Aðalbjörg; Jónasdóttir, Áslaug; Sigurðsson, Ásgeir; Magnússon, Ólafur T.; Eyjólfsson, Guðmundur I.; Ólafsson, Ísleifur; Önundarson, Páll Torfi; Sigurðardóttir, Ólöf; Gíslason, Davíð; Gislason, Thorarinn; Ludviksson, Bjorn; Lúðvíksdóttir, Dóra; Boezen, H. Marike; Heinzmann, Andrea; Krueger, Marcus; Porsbjerg, Celeste; Ahluwalia, Tarunveer S.; Waage, Johannes; Backer, Vibeke; Deichmann, Klaus A.; Koppelman, Gerard H.; Bønnelykke, Klaus; Bisgaard, Hans; Másson, Gísli; Thorsteinsdottir, Unnur; Gudbjartsson, Daniel; Johnston, James A.; Jonsdottir, Ingileif; Stefansson, Kari (Public Library of Science (PLoS), 2017-03-08)
    IL-33 is a tissue-derived cytokine that induces and amplifies eosinophilic inflammation and has emerged as a promising new drug target for asthma and allergic disease. Common variants at IL33 and IL1RL1, encoding the IL-33 receptor ST2, associate with ...